The pipeline for dry eye disease drugs is beginning to heat ... and Allergan's ageing Restasis potentially facing generic competition, there’s a lot to play for and two biotechs are aiming ...
Dry Eye Disease (DED) is the most common ocular surface disorder ... In addition, Link_TSG6 was significantly more effective than Restasis â, the market leading treatment, at reducing corneal ...
"In contrast to currently available dry eye therapies that may require weeks ... like Novartis' Xiidra (lifitegrast) and AbbVie's Restasis (cyclosporine), which are not considered to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results